BioSpace News Archive

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate

BrainTale, a French innovative company dedicated to enabling adapted care for brain injured patients in clinical routine with its portfolio of quantification and prediction digital medical devices in neurology and intensive care, announced the completion of its first financing round securing more than 1M€ of funding.

Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the presentation of new data from two ongoing clinical trials evaluating CMP-001, Checkmate’s Toll-like receptor 9 (TLR9) agonist,

Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2020.

TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ:TOMZ) is a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products - a hydrogen peroxide-based mist and fog comprised of ionized Hydrogen Peroxide (iHP).

Pierre Fabre announced today the initiation of an international Phase I clinical study in patients with relapsed or refractory solid tumors for its investigational product W0180, an innovative monoclonal antibody targeting VISTA, developed by Pierre Fabre Medical Care R&D teams.

Study shows hAd5 S+N COVID-19 vaccine candidate, which delivers two distinct proteins, stimulates T-cell responses of volunteers recovered from SARS-CoV-2 infection, demonstrating that the S and N antigens from the vaccine are recognized by SARS-COV-2 reactive human T cells

Aptevo Therapeutics Inc. announced that it will present two new posters at the Society for Immunotherapy of Cancer’s 35th Virtual Annual Meeting, to be held from Monday, November 9, 2020 to Saturday, November 14, 2020.

DERMALA, Inc., a consumer dermatology company developing novel, personalized, microbiome-based solutions for acne and other skin conditions, announced today that it has closed a $6.73 million Series A financing.

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that EUROIMMUN, a PerkinElmer company, has launched the Anti-SARS-CoV-2 QuantiVacTM ELISA (IgG) to quantify IgG antibodies against the SARS-CoV-2 S1 antigen.